Hofseth BioCare ASA reports increased total operating revenues and strong B2B sales in Q1 2025.

From GlobeNewswire: 2025-05-16 02:30:00

HBC reported total operating revenues of NOK 60.9 million in Q1 2025, up from NOK 52.4 million in the same period last year. Net operating revenues were NOK 60.7 million, driven by growth in human and pet health segments. Cost of goods sold increased to NOK 37.5 million. EBITDA was negative NOK 19.9 million.

Key highlights include a 15% increase in total revenues, decision to expand production capacity at Berkåk, and strong B2B sales in the human segment. Organic sales continued to rise, with new product launches and listings on major platforms. Clinical milestones were achieved for OmeGo® and NT-II™, demonstrating health benefits.

Hofseth BioCare ASA is a Norwegian company focused on sustainability and pet health. They upcycle salmon industry byproducts into ingredients like ProGo®, OmeGo®, and CalGo® / NT-II® for human and pet health. Scientific evidence supports various health benefits of their products, leading to academic partnerships and unique health discoveries.



Read more at GlobeNewswire:: FIRST QUARTER 2025 FINANCIAL REPORT